DESIGN THERAPEUTICS INC (DSGN)
Health Care · biotechnology · NASDAQ
Design Therapeutics is a biopharmaceutical company pioneering GeneTAC small-molecule therapies to treat the root causes of serious genetic diseases.
What DESIGN THERAPEUTICS INC does
Design Therapeutics is a clinical-stage biopharmaceutical company focused on developing a proprietary class of small-molecule medicines called GeneTAC (Gene Targeted Chimera) molecules. These molecules are designed to regulate gene expression and treat serious genetic diseases by targeting underlying genetic causes rather than just symptoms. The company's platform aims to address various genetic disorders through the modulation of gene expression.
Themes: gene therapy, genetic diseases, small molecule therapeutics, biotech R&D
Fundamentals
- Price$10.73 as of 2026-10-21 close
- Market cap$672M as of 2026-07-29 (share count; price 2026-10-21)
- 1-year return+90.6% 2025-10-21 close $5.63 → 2026-10-21 close $10.73
- P/En/a negative earnings
- ROE-32.8% FY2025, SEC XBRL
- ROICn/a No figure: its 10-K tags no pre-tax income, so no tax rate can be taken.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Beta1.19 as of 2026-09-03
- Last reported earnings2026-08-03 SEC EDGAR Form 8-K (Item 2.02)
How DSGN compares in its sector
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | — | -$22M | -$20M | -$0.32 | -$16M† | $21000† |
| Q1 FY2026 2026-03-31 | $0 | -$20M | -$18M | -$0.29 | -$16M | $0 |
| Q4 FY2025 2025-12-31 | — | -$18M† | -$16M† | -$0.27† | -$12M† | $34000† |
| Q3 FY2025 2025-09-30 | — | -$19M | -$17M | -$0.30 | -$11M† | $0† |
| Q2 FY2025 2025-06-30 | — | -$22M | -$19M | -$0.34 | -$14M† | $87000† |
| Q1 FY2025 2025-03-31 | $0 | -$20M | -$18M | -$0.31 | -$17M | $72000 |
| Q4 FY2024 2024-12-31 | — | -$17M† | -$14M† | -$0.24† | -$10M† | $0† |
| Q3 FY2024 2024-09-30 | — | -$16M | -$13M | -$0.23 | -$10M† | -$16000† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$13M
- Short-term investments$194M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How DESIGN THERAPEUTICS INC looks technically
DESIGN THERAPEUTICS INC (DSGN) is trading 11.4% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 280 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 30, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 39, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive). It made a new 20-day low about 6 trading days ago. It is 37.8% below its highest point of the past year. Trading volume is unusually light — only about 47% of its 30-day average.
Trend
8
| Distance from the 200-day | it is trading 11.4% below its 200-day average, the long-term trend line — a long-term downtrend | -11.4% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $13.28 | $13.28 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $12.11 | $12.11 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 19 calendar days ago — the swings before that are what the structure reading is measured on | 19 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 12.945. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 280 trading days ago — a "golden cross", a bullish long-term signal | 280 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 30, with sellers in control | 30.4 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 39, neither overbought (above 70) nor oversold (below 30) | 39.5 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($9.47 to $12.95) — its "stochastic" reading is 36 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 36.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive) | 1 session |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $17.25 | $17.25 |
|---|---|---|
| From the 52-week high | it is 37.8% below its 52-week high (its highest price of the past year) | -37.8% |
| Above the 52-week low | it is 103.2% above its 52-week low (its lowest price of the past year) | +103.2% |
| Below the 52-week high | it is 37.8% below its highest point of the past year | 37.8% |
| Since a 20-day breakout | it made a new 20-day low about 6 trading days ago | 6 sessions |
| Since a 55-day breakout | it made a new 55-day low about 6 trading days ago | 6 sessions |
| All-time high | its highest closing price on record is $43.00 (set on 2021-03-29) | $43.00 |
| Given back of the 52-week move | over the past year its closes ranged ($5.53 to $15.94), and it has given back around half of its rise from last year’s low — 50% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $9.17 to $9.51. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 50.0% |
| From the all-time high | it is 75.0% below its all-time high | -75.0% |
| Nearest price level | it is trading 4.2% below a resistance level at $11.19 — a price it turned at twice since 2026-02-25, most recently on 2026-03-16. Since 2024-10-21 it has 9 such levels below the current price and 2 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +4.2% |
| All-time low | its lowest closing price on record is $1.94 (set on 2023-08-22) | $1.94 |
| Above the all-time low | it is 453.1% above its all-time low | +453.1% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 47th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.7102 between its high and its low — about 6.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.7102 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $9.64 and $13.30 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $9.64 – $11.47 – $13.30 |
| Typical daily range (% of price) | its price moves about 6.6% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.6% |
| Stretch from the 200-day average | it is trading 1.9 daily ranges below its 200-day average price (11.4% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.9 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 47% of its 30-day average | 0.47× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a doji | 9 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 9 sessions ago |
|---|---|---|
| Since a bullish engulfing | 8 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 8 sessions ago |
| Since a bearish engulfing | 7 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 7 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-21 at essentially the same price it closed at the session before — no meaningful overnight gap | -0.1% |
|---|---|---|
| Gap filled | a 3.1% gap up opened on 2026-10-02 has been "filled" 13 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 13 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 14.4 percentage points (the stock lost 14.5% while the market lost 0.1%) | -14.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 14.3 percentage points (the stock lost 11.0% while the market gained 3.3%) | -14.3% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 29.1 percentage points (the stock lost 19.3% while the market gained 9.8%) | -29.1% |
| vs market, 12 months | over the past 12 months this stock beat the market by 75.4 percentage points (the stock gained 90.6% while the market gained 15.2%) | +75.4% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, MACD momentum is positive — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 22% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-15 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 2.5% of the share price. | -22.2% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 14% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $12.44 — a volume-weighted average of daily closes over 201 sessions, not a true tick-by-tick VWAP. | -13.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 19% below the average price paid since it last reported on 2026-08-03 (its 10-Q), so the typical buyer over that stretch is under water. That average is $13.27 — a volume-weighted average of daily closes over 57 sessions, not a true tick-by-tick VWAP. | -19.1% |
Double top, bearish — broke down · entry $11.63 · 76 sessions in
Price levels it has turned at before
DSGN last closed at $10.73 on 2026-10-21. Since 2024-10-21 it has turned at 9 prices below its last close and 2 above; the 3 nearest below and the 2 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $11.19 | Resistance | 4.2% above the last close | turned there twice · 2026-02-25 to 2026-03-16 |
| $10.14 | Support | 5.5% below the last close | turned there twice · 2025-12-22 to 2026-01-07 |
| $9.92 | Support | 7.5% below the last close | turned there three times · 2026-03-24 to 2026-06-02 |
| $9.70 | Support | 9.7% below the last close | turned there twice · 2026-02-19 to 2026-03-10 |
| $11.88 | Resistance | 10.8% above the last close | turned there three times · 2026-04-24 to 2026-09-24 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $12.95.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 9 trading days, since 2026-10-09.
Read from daily closes as of 2026-10-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Pulled back from the 12-month high · MACD just crossed bullish (12/26/9) · lagging the market · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-10-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.25 mean, 1=Strong Buy…5=Strong Sell) — 7 analysts
- Mean price target$21.71 range $20.00 – $26.00; median $21.00
Analyst estimates, as of 2026-10-22. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for DSGN
- Consensus EPS estimate-$0.3463 next reporting period, as of 2026-10-22
- Estimate change, 30 days+$0.00661 from -$0.3529, on 2026-09-17, 35-day window
- Readings revised upward13% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["The company is in the clinical stage and has a history of losses, with significant uncertainty regarding future profitability and the ability to successfully develop and commercialize its drug candidates.","Success depends heavily on the clinical and regulatory progress of its proprietary GeneTAC platform and individual drug candidates."]
What changed in the latest 10-Q
AI-assisted comparison of DSGN's 10-Q filed 2026-08-03 against the prior one filed 2026-04-28.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing adds a statement that a Phase 1 SAD clinical trial of DT-216P2 has shown DT-216P2 was generally well-tolerated and that human PK data demonstrated improved exposure and PK parameters compared to DT-216P1, including higher AUC and sustained plasma levels at comparable doses.
- Newer filing adds details that in May 2026, the company announced positive biomarker and clinical data from the four-week IV cohorts in the RESTORE-FA trial showing dose-dependent increases in FXN levels and improvements across multiple clinical measures including mFARS, USS, and patient-reported fatigue after four weeks of IV treatment.
- Newer filing adds specific data from the 1 mpk dose cohort (n=4) showing mean improvements of 6.4 points in mFARS and 2.7 points in USS.
- Newer filing adds that DT-216P2 treatment demonstrated a mean change of greater than five points in patient-reported fatigue as measured by PROMIS Fatigue Scale, exceeding the three-point threshold generally considered a minimal important change.
- Newer filing adds data that whole blood FXN mRNA levels increased by 65% from baseline (p < 0.001) after four weeks of treatment at 1 mpk.
- Newer filing adds data that whole blood FXN-M and FXN-E protein levels increased by 22-27% from baseline two weeks following the last dose (p < 0.001).
- Newer filing adds data that muscle FXN mRNA levels increased by 42% from baseline (p = 0.015).
- Newer filing adds that DT-216P2 was generally well-tolerated with no serious adverse events or treatment discontinuations reported, and all adverse events were mild or moderate.
- Newer filing adds that adverse events considered possibly or probably related to DT-216P2 occurring in more than one patient included mild to moderate transient ALT elevations in three patients, all asymptomatic with no associated increases in bilirubin and on background omaveloxolone.
- Newer filing adds that based on the four-week data, the company is modifying the ongoing cohorts in the RESTORE-FA trial to support the next stage of clinical development, and the study will continue to evaluate 1 mpk as...
- Removed:
- Older filing includes a paragraph on DT-168 that is absent from the newer filing excerpt, describing DT-168 as an eye drop for FECD, including robust reductions in pathogenic nuclear RNA foci in FECD patient-derived corneal endothelial cells, favorable animal model distribution, chronic toxicity studies up to nine months, an observational study in FECD with enrollment of approximately 250 patients and approximately 100 patients chosen for follow-up visits.
- Older filing includes a paragraph on May 2025 Phase 1 DT-168 ophthalmic solution clinical trial results, including that DT-168 eye drops were well-tolerated, with no serious adverse events, no ocular adverse events, and no treatment discontinuations due to adverse events, and reference range studies supporting corneal endothelium biomarkers.
- Reworded:
- Older filing describes the RESTORE-FA trial as a 'Phase 1/2 MAD clinical trial' and a 'multiple ascending dose study' administered through IV or SC over four- or 12-week treatment periods; newer filing describes RESTORE-FA as a 'Phase 1/2 clinical trial' without the MAD or multiple ascending dose description and reframes design details around safety, pharmacokinetics, pharmacodynamics including changes in endogenous FXN, and clinical endpoints.
- Older filing states 'We anticipate providing an update from the RESTORE-FA trial on the effect of DT-216P2 on endogenous frataxin levels in the second half of 2026'; newer filing removes this forward-looking statement and replaces it with reporting of the May 2026 announced data.
- Notes:
- The newer filing excerpt is truncated mid-sentence at 'The study will continue to evaluate 1 mpk as', so further content in the newer MD&A beyond that point is not available for comparison.
- The older filing excerpt is truncated mid-sentence at 'supporting the potential for corneal endothelium biomarkers as a clinical proof-of-concept measure of', so further content in the older MD&A beyond that point is not available for comparison.
- Because both excerpts are truncated, any changes after the truncation points cannot be assessed.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for DSGN — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding DSGN as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 4,752,362
- Reported value $68,766,681
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 2 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about DSGN's institutional holders → See what each manager we track holds →
Short interest (FINRA)
DSGN had 6,616,513 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
DSGN had 10.6% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 8.69 days to cover at the same settlement.
- Reported short interest (shares) 6,616,513
- Short interest (% of shares outstanding) 10.6%
- Prior settlement (shares) 5,461,508
- Reported change 21.15%
- Days to cover (reported) 8.69
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Ionis Pharmaceuticals (IONS)
- Alnylam Pharmaceuticals (ALNY)
- Sarepta Therapeutics (SRPT)
- Vertex Pharmaceuticals (VRTX)
- Biogen (BIIB)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare DSGN vs…
DESIGN THERAPEUTICS INC is found in…
Frequently asked questions
What does DESIGN THERAPEUTICS INC (DSGN) do?
Design Therapeutics is a clinical-stage biopharmaceutical company focused on developing a proprietary class of small-molecule medicines called GeneTAC (Gene Targeted Chimera) molecules. These molecules are designed to regulate gene expression and treat serious genetic diseases by targeting underlying genetic causes rather than just symptoms. The company's platform aims to address various genetic disorders through the modulation of gene expression.
What sector is DESIGN THERAPEUTICS INC (DSGN) in?
DESIGN THERAPEUTICS INC (DSGN) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are DESIGN THERAPEUTICS INC's (DSGN) competitors?
Notable peers of DESIGN THERAPEUTICS INC (DSGN) include Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Sarepta Therapeutics, Vertex Pharmaceuticals and Biogen. This peer set is informational only — not financial advice.
Is DESIGN THERAPEUTICS INC (DSGN) overbought or oversold right now?
DESIGN THERAPEUTICS INC (DSGN) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 39, in the neutral middle (as of 2026-10-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on DSGN come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.